Conatus Pharmaceuticals (CNAT) Shares Down 6.8%

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) shares fell 6.8% on Friday . The stock traded as low as $5.22 and last traded at $5.34. 622,677 shares traded hands during trading, an increase of 1% from the average session volume of 618,319 shares. The stock had previously closed at $5.73.

CNAT has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating on shares of Conatus Pharmaceuticals in a research report on Monday. ValuEngine downgraded shares of Conatus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 1st. Finally, Oppenheimer set a $14.00 price target on shares of Conatus Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 1st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $11.80.

The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 2.39. The stock has a market capitalization of $156.76 million, a PE ratio of -8.75 and a beta of 1.84.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.15). Conatus Pharmaceuticals had a negative net margin of 52.77% and a negative return on equity of 83.99%. The company had revenue of $7.67 million for the quarter, compared to the consensus estimate of $9.70 million. On average, sell-side analysts forecast that Conatus Pharmaceuticals Inc will post -0.6 EPS for the current year.

Several institutional investors have recently bought and sold shares of CNAT. BlackRock Inc. lifted its position in shares of Conatus Pharmaceuticals by 45.4% in the 1st quarter. BlackRock Inc. now owns 2,316,808 shares of the biotechnology company’s stock worth $13,601,000 after buying an additional 723,413 shares during the last quarter. Artal Group S.A. bought a new position in shares of Conatus Pharmaceuticals in the 3rd quarter worth about $2,900,000. Alambic Investment Management L.P. lifted its position in shares of Conatus Pharmaceuticals by 207.0% in the 2nd quarter. Alambic Investment Management L.P. now owns 264,665 shares of the biotechnology company’s stock worth $1,133,000 after buying an additional 178,461 shares during the last quarter. Paloma Partners Management Co bought a new stake in Conatus Pharmaceuticals in the 2nd quarter valued at about $547,000. Finally, LMR Partners LLP bought a new stake in Conatus Pharmaceuticals in the 2nd quarter valued at about $311,000. Institutional investors own 33.47% of the company’s stock.

WARNING: This report was first posted by WKRB News and is the property of of WKRB News. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.wkrb13.com/2018/11/10/conatus-pharmaceuticals-cnat-shares-down-6-8.html.

About Conatus Pharmaceuticals (NASDAQ:CNAT)

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Recommended Story: What are the economic characteristics of a bear market?

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply